Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): An uncontrolled feasibility study of novel nicotine replacement products among people living with HIV (PLHIV) who smoke

The University of Queensland0 sites30 target enrollmentNovember 28, 2016

Overview

No summary available.

Registry

who.int

Start Date

November 28, 2016

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\.A diagnosis of HIV
•2\.Aged 18 years (or over)
•3\.Smoke 5 (or more) cigarettes per day, at the time of enrolment into the trial
•4\.Have been smoking for at least 12 months
•5\.Have capacity to consent and able to understand study instructions and procedures (e.g. sufficient English language ability).
•6\.Willing to attempt to quit tobacco smoking within 1 week of enrolment

•1\.Currently participating in a smoking\-cessation program
•2\.Aged \<18 years
•3\.Currently pregnant, measured by self\-report, with confirmation by self\-administered pregnancy test where there is doubt, or planning to become pregnant during trial participation period
•4\.Currently breast\-feeding (measured by self\-report) or planning to be during trial participation period
•5\.Insufficient capacity to provide informed consent or complete the study requirements (e.g. completing surveys in English)
•6\.Has experienced chest pain, or another cardiovascular event or procedure (e.g. heart attack, stroke, insertion of stent, bypass surgery) in the last month
•7\.Being treated with oxygen therapy.